pI: 6.7611 |
Length (AA): 532 |
MW (Da): 58958 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There is 1 model calculated for this protein. More info on
this model, including the
model itself is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
350 | 495 | 2gys (A) | 69 | 237 | 30.00 | 0.44 | 0.02 | 0.124636 | 2.07 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | metacyclic. | Smircich P |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | epimastigote. | Smircich P |
Smircich P | Ribosome profiling reveals translation control as a key mechanism generating differential gene expression in Trypanosoma cruzi. |
Ortholog group members (OG5_157739)
Species | Accession | Gene Product |
---|---|---|
Leishmania braziliensis | LbrM.35.5800 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_365770.1 | Phosphorylated CTD interacting factor 1 WW domain containing protein, putative |
Leishmania major | LmjF.36.5530 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.36.5530 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.509799.80 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.504137.130 | hypothetical protein, conserved |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.